Handelen Gilead Sciences - GILD CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.14 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Gilead Sciences Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 79.13 |
| Open* | 79.08 |
| 1-Jaarlijkse Verandering* | 32.68% |
| Dagelijks bereik* | 78.04 - 79.23 |
| 52 wekelijks bereik | 57.17-89.74 |
| Weekgemiddelde volume (10 dagen) | 6.97M |
| Gemiddeld volume (3 maanden) | 127.33M |
| Marktkapitalisatie | 99.10B |
| P/E Ratio | 21.84 |
| Uitstaande Aandelen | 1.25B |
| Omzet | 27.28B |
| EPS | 3.64 |
| Dividend (opbrengst %) | 3.77548 |
| Beta | 0.40 |
| Volgende inkomsten datum | Apr 26, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2023 | 78.29 | -0.99 | -1.25% | 79.28 | 79.96 | 78.29 |
| Mar 20, 2023 | 78.82 | 2.26 | 2.95% | 76.56 | 79.59 | 76.14 |
| Mar 17, 2023 | 77.23 | -2.28 | -2.87% | 79.51 | 79.78 | 76.46 |
| Mar 16, 2023 | 78.98 | 0.19 | 0.24% | 78.79 | 79.88 | 77.74 |
| Mar 15, 2023 | 78.98 | -0.65 | -0.82% | 79.63 | 79.82 | 78.03 |
| Mar 14, 2023 | 78.62 | -0.12 | -0.15% | 78.74 | 79.83 | 78.24 |
| Mar 13, 2023 | 79.28 | -0.26 | -0.33% | 79.54 | 81.19 | 76.94 |
| Mar 10, 2023 | 79.00 | 0.48 | 0.61% | 78.52 | 80.24 | 77.61 |
| Mar 9, 2023 | 78.90 | -0.83 | -1.04% | 79.73 | 80.58 | 78.22 |
| Mar 8, 2023 | 79.73 | -0.36 | -0.45% | 80.09 | 80.68 | 79.48 |
| Mar 7, 2023 | 79.79 | -0.94 | -1.16% | 80.73 | 81.23 | 79.79 |
| Mar 6, 2023 | 81.04 | 0.27 | 0.33% | 80.77 | 81.25 | 80.35 |
| Mar 3, 2023 | 80.57 | 1.14 | 1.44% | 79.43 | 81.09 | 79.03 |
| Mar 2, 2023 | 79.43 | -0.05 | -0.06% | 79.48 | 79.83 | 78.44 |
| Mar 1, 2023 | 79.31 | -0.98 | -1.22% | 80.29 | 80.58 | 78.93 |
| Feb 28, 2023 | 79.96 | -0.55 | -0.68% | 80.51 | 80.92 | 79.28 |
| Feb 27, 2023 | 80.53 | 0.05 | 0.06% | 80.48 | 81.24 | 79.61 |
| Feb 24, 2023 | 80.59 | -1.69 | -2.05% | 82.28 | 82.49 | 80.13 |
| Feb 23, 2023 | 82.19 | -0.74 | -0.89% | 82.93 | 83.77 | 82.10 |
| Feb 22, 2023 | 82.93 | -1.75 | -2.07% | 84.68 | 84.83 | 82.93 |
Gilead Sciences Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale inkomsten | 27305 | 24689 | 22449 | 22127 | 26107 |
| Inkomsten | 27305 | 24689 | 22449 | 22127 | 26107 |
| Kosten van opbrengsten, totaal | 6601 | 4572 | 4675 | 4853 | 4371 |
| Brutowinst | 20704 | 20117 | 17774 | 17274 | 21736 |
| Totale bedrijfskosten | 17387 | 20618 | 18162 | 13927 | 11983 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 5246 | 5151 | 4381 | 4056 | 3830 |
| Onderzoek & Ontwikkeling | 5540 | 10895 | 8934 | 4846 | 3512 |
| Ongebruikelijke uitgaven (inkomsten) | 172 | 172 | 270 | ||
| Bedrijfsresultaat | 9918 | 4071 | 4287 | 8200 | 14124 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1611 | -2684 | 227 | -964 | -1190 |
| Overige, Netto | -29 | 282 | 646 | 563 | 595 |
| Netto inkomen voor belastingen | 8278 | 1669 | 5160 | 7799 | 13529 |
| Netto inkomen na belastingen | 6201 | 89 | 5364 | 5464 | 10136 |
| Minderheidsbelang | 24 | 34 | 22 | -5 | -16 |
| Netto inkomen voor extra. Posten | 6225 | 123 | 5386 | 5459 | 10120 |
| Netto inkomen | 6225 | 123 | 5386 | 5455 | 4628 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 6225 | 123 | 5386 | 5459 | 10120 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 6225 | 123 | 5386 | 5455 | 4628 |
| Verwateringsaanpassing | |||||
| Verwaterd Netto Inkomen | 6225 | 123 | 5386 | 5455 | 4628 |
| Verwaterd Gewogen Gemiddelde Aandelen | 1262 | 1263 | 1277 | 1308 | 1319 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 4.93265 | 0.09739 | 4.2177 | 4.17355 | 7.67248 |
| Dividends per Share - Common Stock Primary Issue | 2.84 | 2.72 | 2.52 | 2.28 | 2.08 |
| Verwaterde Genormaliseerde Winst per Aandeel | 4.93265 | 0.09739 | 4.30525 | 4.26568 | 7.82584 |
| Totale buitengewone posten | -4 | -5492 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 6590 | 7244 | 7421 | 6217 | 6423 |
| Inkomsten | 6590 | 7244 | 7421 | 6217 | 6423 |
| Kosten van opbrengsten, totaal | 1424 | 2627 | 1223 | 1390 | 1361 |
| Brutowinst | 5166 | 4617 | 6198 | 4827 | 5062 |
| Totale bedrijfskosten | 6393 | 6304 | 3579 | 3971 | 3533 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 1083 | 1650 | 1190 | 1351 | 1044 |
| Onderzoek & Ontwikkeling | 1186 | 2027 | 1166 | 1230 | 1117 |
| Ongebruikelijke uitgaven (inkomsten) | 2700 | 11 | |||
| Bedrijfsresultaat | 197 | 940 | 3842 | 2246 | 2890 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -334 | -181 | -392 | -430 | -608 |
| Overige, Netto | -15 | -12 | 1 | -18 | |
| Netto inkomen voor belastingen | -152 | 759 | 3438 | 1817 | 2264 |
| Netto inkomen na belastingen | 12 | 376 | 2586 | 1517 | 1722 |
| Minderheidsbelang | 7 | 6 | 6 | 5 | 7 |
| Netto inkomen voor extra. Posten | 19 | 382 | 2592 | 1522 | 1729 |
| Netto inkomen | 19 | 382 | 2592 | 1522 | 1729 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 19 | 382 | 2592 | 1522 | 1729 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 19 | 382 | 2592 | 1522 | 1729 |
| Verwaterd Netto Inkomen | 19 | 382 | 2592 | 1522 | 1729 |
| Verwaterd Gewogen Gemiddelde Aandelen | 1262 | 1262 | 1262 | 1260 | 1262 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.01506 | 0.30269 | 2.05388 | 1.20794 | 1.37005 |
| Dividends per Share - Common Stock Primary Issue | 0.73 | 0.71 | 0.71 | 0.71 | 0.71 |
| Verwaterde Genormaliseerde Winst per Aandeel | 1.40571 | 0.30269 | 2.05388 | 1.20794 | 1.37668 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 14772 | 15996 | 30296 | 35836 | 31823 |
| Geldmiddelen en kortetermijnbeleggingen | 6520 | 7408 | 24352 | 30089 | 25510 |
| Geldmiddelen & Equivalenten | 5338 | 5997 | 11631 | 17940 | 7588 |
| Korte Termijn Investeringen | 1182 | 1411 | 12721 | 12149 | 17922 |
| Totale Vorderingen, Netto | 4493 | 4892 | 3582 | 3327 | 3851 |
| Accounts Receivable - Trade, Net | 4493 | 4892 | 3582 | 3327 | 3851 |
| Total Inventory | 1618 | 1683 | 922 | 814 | 801 |
| Prepaid Expenses | 2141 | 2013 | 1403 | 1533 | 1649 |
| Total Assets | 67952 | 68407 | 61627 | 63675 | 70283 |
| Property/Plant/Equipment, Total - Net | 5663 | 5613 | 5170 | 4006 | 3295 |
| Goodwill, Net | 8332 | 8108 | 4117 | 4117 | 4159 |
| Intangibles, Net | 33455 | 33126 | 13786 | 15738 | 17100 |
| Long Term Investments | 1309 | 502 | 1488 | 1423 | 11194 |
| Other Long Term Assets, Total | 4421 | 5062 | 6770 | 2555 | 2712 |
| Total Current Liabilities | 11610 | 11397 | 9759 | 10605 | 11635 |
| Accounts Payable | 705 | 844 | 713 | 790 | 814 |
| Accrued Expenses | 7600 | 7198 | 6254 | 6876 | 7271 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1516 | 2757 | 2499 | 2748 | 2747 |
| Other Current Liabilities, Total | 1789 | 598 | 293 | 191 | 803 |
| Total Liabilities | 46883 | 50205 | 39102 | 42288 | 49841 |
| Total Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
| Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
| Minority Interest | -5 | 19 | 125 | 147 | 59 |
| Other Liabilities, Total | 5743 | 10144 | 7124 | 6962 | 7352 |
| Total Equity | 21069 | 18202 | 22525 | 21387 | 20442 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4661 | 3880 | 3051 | 2282 | 1264 |
| Retained Earnings (Accumulated Deficit) | 16324 | 14381 | 19388 | 19024 | 19012 |
| Unrealized Gain (Loss) | -4 | 2 | 1 | -52 | 194 |
| Other Equity, Total | 87 | -62 | 84 | 132 | -29 |
| Total Liabilities & Shareholders’ Equity | 67952 | 68407 | 61627 | 63675 | 70283 |
| Total Common Shares Outstanding | 1254 | 1254 | 1266 | 1282 | 1308 |
| Other Current Assets, Total | 37 | 73 | 12 | ||
| Property/Plant/Equipment, Total - Gross | 7556 | 7281 | 6592 | 5197 | 4289 |
| Accumulated Depreciation, Total | -1893 | -1668 | -1422 | -1191 | -994 |
| Deferred Income Tax | 4356 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 12629 | 14772 | 13991 | 13925 | 13278 |
| Geldmiddelen en kortetermijnbeleggingen | 5325 | 6520 | 5738 | 6525 | 5666 |
| Geldmiddelen & Equivalenten | 4296 | 5338 | 4362 | 4893 | 4065 |
| Korte Termijn Investeringen | 1029 | 1182 | 1376 | 1632 | 1601 |
| Totale Vorderingen, Netto | 3787 | 4493 | 4566 | 4149 | 3925 |
| Accounts Receivable - Trade, Net | 3787 | 4493 | 4566 | 4149 | 3925 |
| Total Inventory | 1482 | 1618 | 1676 | 1772 | 1779 |
| Prepaid Expenses | 2035 | 2141 | 2011 | 1479 | 1908 |
| Total Assets | 63080 | 67952 | 67098 | 67984 | 67492 |
| Property/Plant/Equipment, Total - Net | 5253 | 5121 | 5037 | 4996 | 4990 |
| Goodwill, Net | 8314 | 8332 | 8332 | 8334 | 8334 |
| Intangibles, Net | 30331 | 33455 | 33900 | 34341 | 34781 |
| Long Term Investments | 1427 | 1309 | 1099 | 836 | 579 |
| Other Long Term Assets, Total | 5126 | 4963 | 4739 | 5552 | 5530 |
| Total Current Liabilities | 8558 | 11610 | 10245 | 10214 | 9705 |
| Accounts Payable | 583 | 705 | 585 | 608 | 570 |
| Accrued Expenses | 6483 | 7600 | 6702 | 6906 | 6661 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1025 | 1516 | 2511 | 2261 | 2259 |
| Other Current Liabilities, Total | 467 | 1789 | 447 | 439 | 215 |
| Total Liabilities | 43153 | 46883 | 45628 | 48281 | 48540 |
| Total Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
| Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
| Deferred Income Tax | 3687 | 4356 | 4603 | 4374 | 4464 |
| Minority Interest | -12 | -5 | 1 | 7 | 12 |
| Other Liabilities, Total | 5737 | 5743 | 5604 | 5772 | 6452 |
| Total Equity | 19927 | 21069 | 21470 | 19703 | 18952 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4867 | 4661 | 4492 | 4271 | 4092 |
| Retained Earnings (Accumulated Deficit) | 14986 | 16324 | 16903 | 15392 | 14821 |
| Unrealized Gain (Loss) | -23 | -4 | -1 | -1 | 0 |
| Other Equity, Total | 96 | 87 | 75 | 40 | 38 |
| Total Liabilities & Shareholders’ Equity | 63080 | 67952 | 67098 | 67984 | 67492 |
| Total Common Shares Outstanding | 1255 | 1254 | 1255 | 1254 | 1254 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | 6201 | 89 | 5364 | 5460 | 4644 |
| Geldmiddelen uit Operationele Activiteiten | 11384 | 8168 | 9144 | 8400 | 11898 |
| Geldmiddelen uit Operationele Activiteiten | 329 | 288 | 255 | 226 | 233 |
| Amortization | 1721 | 1192 | 1149 | 1203 | 1053 |
| Deferred Taxes | -116 | -214 | -2098 | 289 | -82 |
| Niet-Geldelijke Posten | 2760 | 8451 | 5272 | 2161 | 942 |
| Cash Taxes Paid | 2509 | 2639 | 1793 | 3198 | 3342 |
| Contant Betaalde Rente | 979 | 951 | 982 | 1070 | 1038 |
| Veranderingen in het Operationeel Kapitaal | 489 | -1638 | -798 | -939 | 5108 |
| Geldmiddelen uit Investeringsactiviteiten | -3131 | -14615 | -7817 | 14355 | -16069 |
| Kapitaaluitgaven | -579 | -650 | -825 | -924 | -590 |
| Overige Cash Flow investeringsposten, Totaal | -2552 | -13965 | -6992 | 15279 | -15479 |
| Geldmiddelen uit Financieringsactiviteiten | -8877 | 770 | -7634 | -12318 | 3393 |
| Financiering van Cash Flow Posten | -145 | -138 | -122 | -486 | -330 |
| Total Cash Dividends Paid | -3605 | -3449 | -3222 | -2971 | -2731 |
| Uitgifte (Aflossing) van aandelen, netto | -377 | -1327 | -1540 | -2611 | -720 |
| Uitgifte (Aflossing) van Schulden, Netto | -4750 | 5684 | -2750 | -6250 | 7174 |
| Wisselkoerseffecten | -35 | 43 | -2 | -85 | 137 |
| Nettowijziging in Geldmiddelen | -659 | -5634 | -6309 | 10352 | -641 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 12 | 6201 | 5825 | 3239 | 1722 |
| Cash From Operating Activities | 1840 | 11384 | 8179 | 4926 | 2610 |
| Cash From Operating Activities | 80 | 329 | 239 | 157 | 78 |
| Amortization | 445 | 1721 | 1276 | 835 | 395 |
| Deferred Taxes | -651 | -116 | 243 | 3 | 71 |
| Non-Cash Items | 3116 | 2760 | 1921 | 1564 | 753 |
| Changes in Working Capital | -1162 | 489 | -1325 | -872 | -409 |
| Cash From Investing Activities | -1070 | -3131 | -2853 | -2619 | -2042 |
| Capital Expenditures | -247 | -579 | -423 | -284 | -165 |
| Other Investing Cash Flow Items, Total | -823 | -2552 | -2430 | -2335 | -1877 |
| Cash From Financing Activities | -1794 | -8877 | -6935 | -3408 | -2477 |
| Financing Cash Flow Items | -91 | -145 | -134 | -95 | -89 |
| Total Cash Dividends Paid | -945 | -3605 | -2711 | -1811 | -917 |
| Issuance (Retirement) of Stock, Net | -258 | -377 | -340 | -252 | -221 |
| Issuance (Retirement) of Debt, Net | -500 | -4750 | -3750 | -1250 | -1250 |
| Foreign Exchange Effects | -18 | -35 | -26 | -3 | -23 |
| Net Change in Cash | -1042 | -659 | -1635 | -1104 | -1932 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9329 | 111403199 | -68465 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.025 | 87609319 | 3078449 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 5.5242 | 68892972 | 11130228 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7263 | 58941373 | -298977 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.3784 | 54602952 | 727482 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.8775 | 35885152 | -484100 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9123 | 23848477 | 244886 | 2022-12-31 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.3088 | 16322394 | 84245 | 2023-02-28 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.224 | 15265179 | 12533445 | 2022-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 1.1113 | 13859234 | 761084 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0416 | 12989939 | -106202 | 2022-12-31 | LOW |
| Parnassus Investments, LLC | Investment Advisor | 0.9672 | 12062537 | 295282 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8569 | 10686823 | -393685 | 2022-12-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7805 | 9733453 | -126327 | 2022-12-31 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.7772 | 9693019 | -93438 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7531 | 9391729 | -99918 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.7379 | 9202568 | -820000 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7195 | 8972729 | -116113 | 2022-12-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.692 | 8630001 | -344541 | 2022-12-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6788 | 8465274 | -377056 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Gilead Company profile
Over Gilead Sciences
Gilead Sciences, Inc. is een biofarmaceutisch bedrijf. Het bedrijf richt zich op het ontdekken, ontwikkelen en op de markt brengen van geneesmiddelen ter voorkoming en behandeling van ziekten, waaronder het humaan immunodeficiëntievirus (HIV), virale hepatitis en kanker. De producten van het bedrijf voor HIV/AIDS-patiënten omvatten Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, en Atripla. Het COVID-19-product is Veklury. De producten voor leverziekten omvatten Epclusa, Harvoni, Vosevi, Vemlidy en Viread. De producten voor hematologie/oncologie/celtherapie omvatten Yescarta, Tecartus, Trodelvy, en Zydelig. De andere producten omvatten Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, en AmBisome (amfotericine B liposoom voor injectie). De Vennootschap verkoopt en verdeelt ook generische versies van Epclusa en Harvoni in de Verenigde Staten. Zij verkoopt en distribueert haar producten in de Verenigde Staten via het groothandelskanaal. Zij is actief in meer dan 35 landen wereldwijd.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen